Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter:

8 analysts offering 12-month price targets in the last 3 months for Biohaven Pharma Hldgs evaluate the company at an average price target of $97.25 with a high of $140.00 and a low of $69.00.

This current average has increased by 0.11% from the previous average price target of $97.14.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.